Fortress Biotech Files 8-K with Office and Name Change Info

Ticker: FBIOP · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1429260

Fortress Biotech, INC. 8-K Filing Summary
FieldDetail
CompanyFortress Biotech, INC. (FBIOP)
Form Type8-K
Filed DateJul 16, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-info, name-change

Related Tickers: FBIO

TL;DR

FBIO updated its address and confirmed a past name change. Nothing major.

AI Summary

On July 16, 2025, Fortress Biotech, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154. The company's phone number is (781) 652-4500. Fortress Biotech, Inc. was formerly known as Coronado Biosciences Inc. until March 10, 2008.

Why It Matters

This filing provides updated corporate information, including the company's principal executive office address and a historical name change, which is important for investors tracking corporate structure and official communications.

Risk Assessment

Risk Level: low — The filing is administrative and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

FAQ

What is the current principal executive office address for Fortress Biotech, Inc.?

The principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.

What was Fortress Biotech, Inc.'s former name?

Fortress Biotech, Inc. was formerly known as Coronado Biosciences Inc.

When did the company change its name from Coronado Biosciences Inc.?

The date of the name change was March 10, 2008.

What is the phone number listed for Fortress Biotech, Inc.?

The phone number listed is (781) 652-4500.

What is the filing date of this 8-K report?

The report was filed on July 16, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Fortress Biotech, Inc. (FBIOP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing